

Amendments to the Specification

Please replace the paragraph beginning at page 12, line 28 with the following amended paragraph:

--Identification of the factors by HPLC/MS/MS and by sequence analysis revealed four peptides with the following sequence:

H-Lys-Gly-Asn-Tyr-Ala-Glu-Arg-Ileu-Ala-OH (peptide III; SEQ ID NO:1)

H-Thr-Thr-Asp-Thr-Glu-Phe-Glu-Ala-Ala-Gly-Gly-Gly-Val-Arg-OH (peptide VII; SEQ ID NO:4)

H-Thr-Asp-Thr-Glu-Phe-Glu-Ala-Ala-Gly-Gly-Gly-Val-Arg-OH (peptide VI; SEQ ID NO:3)

H-Asp-Thr-Glu-Phe-Glu-Ala-Ala-Gly-Gly-Gly-Val-Arg-OH (peptide IV; SEQ ID NO:2)--

Please replace the paragraph beginning at page 18, line 20 with the following amended paragraph:

--C) Antipain, Leupeptin, p-Aminobenzoyl-Gly-Pro-D-Leu-D-Ala Hydroxamic Acid of SEQ ID NO:15, Elastaminal, phosphoramidon, Bestatin, N-CBZ-PRO-Leu-Gly-Hydroxamate and Puromycin-dihydrochloride; 1mg of each inhibitor was dissolved in 100 µl 0.9% NaCl;--

Please replace the paragraph beginning at page 23, line 24 with the following amended paragraph:

--3b H-Lys¹-Gly²-Asn³-Tyr⁴-**Me**Ala⁵-Glu⁶-Arg⁷-Ileu⁸-Ala⁹-OH (SEQ ID NO:5) 80**
3g H-Lys¹-Gly²-Asn³-Tyr⁴-Ala⁵-Glu⁶-Arg⁷-**Me**Ileu⁸-Ala²-OH (SEQ ID NO:6) 72*
3d H-Lys¹-**Me**Gly²-Asn³-Tyr⁴-Ala⁵-Glu⁶-Arg⁷-Ileu⁸-Ala⁹-OH (SEQ ID NO:7) 39
3e H-Lys¹-**Me**Gly²-Asn³-Tyr⁴-Ala⁵-Glu⁶-Arg⁷-**Me**Ileu⁸-Ala⁹-OH (SEQ ID NO:8) 31
3h H-Lys¹-**Me**Gly²-Asn³-Tyr⁴-**Me**Ala⁵-Glu⁶-Arg⁷-**Me**Ileu⁸-Ala⁹-OH (SEQ ID NO:16) 0--

Please replace the paragraph beginning at page 24, line 23 with the following amended paragraph:

--H-Lys¹-Gly²-Asn³-Tyr⁴-*Me*Ala⁵-Glu⁶-Arg⁷-Ileu⁸-Ala⁹-OH (peptide 3b; SEQ ID NO:5)

H-Asp-Thr-Glu-Phe-Glu-Ala-Ala-Gly-Gly-Gly-Val-Arg-OH (peptide IV; SEQ ID NO:2)--

Please replace the paragraph beginning at page 26, line 16 with the following amended paragraph:

--H-Lys-Gly-Asn-Tyr-Ser-Glu-Arg-Val-Gly-OH (peptide 3m; SEQ ID NO:11)

H-Lys-Gly-His-Tyr-Ala-Glu-Arg-Val-Gly-OH (peptide 3m1; SEQ ID NO:13)

H-Asp-Thr-Glu-Phe-Glu-Ala-Ala-Gly-Gly-Gly-Val-Arg-OH (peptide IV; SEQ ID NO:2)--